IOM review of drug safety system could hurt FDA, industry
The FDA requested the Institute of Medicine conduct a yearlong review of the U.S. drug safety system in the wake of the Vioxx controversy, but agency officials supposedly are unhappy with reports of the committee’s deliberations. The final report is expected to be released in July, which could impact congressional action on an important funding bill for the FDA or spark calls for widespread reforms that could hurt the drug industry.
Assessment of the U. S. Drug Safety System - Institute of Medicine
Can the Institute of Medicine review the FDA? - Nature Medicine
Keep an eye out for this report in about a month.
Technorati Tags: drug safety, FDA
Related Posts:
Bookmark it with:
| 
del.icio.us
| 
Digg it
| 
Furl
| 
Simpy
| 
Spurl
| 
My Yahoo!
|
